Night Sweats — Risk-stratified Assessment

Safety

Red Flags — Risk-stratify for malignancy and serious infection

Done

Night sweats require risk-stratified assessment. First confirm that they are genuine drenching sweats, then look for associated fever, weight loss, lymphadenopathy, respiratory symptoms, immunosuppression, medication causes and menopausal or sleep-related symptoms. Many causes are benign — environmental heat, menopause, medication, alcohol, anxiety and sleep disorders.

Concerning constitutional symptoms Drenching night sweats, documented fever, or unexplained weight loss of more than 10% over 6 months — any one, not necessarily together. These do not diagnose lymphoma ("B symptoms" is a lymphoma staging term) but should prompt full node/spleen examination and targeted investigation (FBC, CRP/ESR, chest X-ray where indicated); if nodes or spleen are found see below. Unexplained weight loss without a site → consider a non-site-specific symptoms (rapid diagnostic) pathway where available

Persistent fever Documented persistent fever with night sweats requires urgent clinical assessment (TB, endocarditis, abscess, HIV). Same-day hospital assessment if systemically unwell, sepsis features, haemodynamic or respiratory compromise, significant immunosuppression, or suspected endocarditis/TB. A stable patient with prolonged low-grade fever may need urgent investigation rather than same-day admission

Same-day hospital or specialist assessment Sepsis, haemodynamic instability or severe systemic illness · suspected endocarditis · severe respiratory compromise · suspected active TB with significant illness · acute neurological symptoms · severe alcohol withdrawal · blasts or a very concerning blood film · severe immunosuppression with fever or suspected opportunistic infection

HIV in the differential Offer an HIV test where HIV is part of the differential diagnosis, particularly with unexplained fever, weight loss, lymphadenopathy, TB, lymphoma, recurrent pneumonia, relevant sexual or injecting-drug exposure, or origin from a higher-prevalence country or group. Use opt-out testing and local prevalence guidance where applicable (NICE NG60; QS157)

Possible active pulmonary TB Consider in persistent cough, fever, night sweats, weight loss or haemoptysis, particularly with relevant travel, country-of-origin, contact, congregate-setting or immunosuppression risk → chest X-ray and urgent TB-service advice. If pulmonary TB is suspected or the chest X-ray is suggestive, send three deep-cough sputum samples for microscopy and culture, preferably including one early-morning sample (NICE NG33); request rapid molecular testing where indicated by the TB service/laboratory

Suspected TB — infection control Avoid unnecessary waiting-room exposure; arrange respiratory hygiene and minimise contact with vulnerable people until assessed. Do not perform sputum induction or other aerosol-generating procedures in an ordinary GP consultation room. Refer suspected active TB urgently — do not manage it with repeated empirical antibiotics

New heart murmur + persistent fever Possible infective endocarditis, especially with embolic features, prosthetic valve, previous endocarditis, intracardiac device or injecting drug use (dental procedures alone are not sufficient to suggest it) → same-day hospital assessment via the local suspected-endocarditis pathway. Obtain blood cultures before antibiotics where this will not delay treatment; if septic or unstable, give urgent hospital treatment and do not delay antibiotics for cultures

Unexplained lymphadenopathy — NICE NG12 (updated April 2026) Adults: consider a suspected cancer pathway referral for Hodgkin lymphoma with unexplained lymphadenopathy, or for non-Hodgkin lymphoma with unexplained lymphadenopathy or splenomegaly, taking into account associated symptoms — particularly fever, night sweats, shortness of breath, pruritus or weight loss (and alcohol-induced node pain for Hodgkin). Children and young people: NG12 suggests considering a very urgent referral for unexplained lymphadenopathy, taking associated symptoms into account — check the current local paediatric pathway; it does not apply to every child with night sweats and lymphadenopathy → Suspected cancer: haematology. Night sweats in isolation are not an NG12 suspected cancer criterion. Do not reassure solely because the FBC is normal when lymphadenopathy is persistent or suspicious

Possible myeloma Night sweats alone do not indicate myeloma. In an older adult with persistent bone pain, unexplained fracture, anaemia, hypercalcaemia, renal impairment, raised ESR/plasma viscosity or recurrent infection, consider myeloma → FBC, calcium, renal function, ESR/plasma viscosity, serum protein electrophoresis and serum free light chains according to local pathway; if these suggest myeloma → Suspected cancer: haematology

Immunocompromised HIV+, transplant, biologics, steroids + night sweats → opportunistic infection or reactivated TB; same-day assessment if febrile or opportunistic infection is suspected, otherwise urgent specialist advice

Pallor, fatigue, bruising, recurrent infection, hepatosplenomegaly NICE NG12: consider a very urgent FBC (within 48 hours) to assess for leukaemia → same-day haematology if the film suggests acute leukaemia

Haemoptysis, aged 40+ NICE NG12: unexplained haemoptysis at 40 or over, or chest X-ray findings suggesting lung cancer → suspected cancer pathway referral for lung cancer → Suspected cancer: lung

Lymphoma (particularly Hodgkin's lymphoma) may present with fever, drenching night sweats or weight loss — in lymphoma terminology "B symptoms" are any of these, not all three together, and the term is used for staging and prognosis rather than as a primary-care diagnosis. Hodgkin lymphoma is highly curable, and outcomes are best when it is diagnosed before advanced-stage disease. Note that NG12 anchors lymphoma referral on unexplained lymphadenopathy (or splenomegaly for non-Hodgkin lymphoma), with night sweats as a weighting symptom — sweats alone, without nodes or spleen, call for risk-stratified assessment and targeted investigation rather than an automatic suspected cancer pathway referral. TB remains an important cause of night sweats in England, concentrated in large cities, in people born in higher-incidence countries, and in those with social risk factors such as homelessness, drug use or imprisonment (UKHSA TB surveillance). HIV can cause night sweats at any stage — offer testing where HIV is part of the differential diagnosis. Infective endocarditis is the must-not-miss cardiac cause.

Diagnose

History — Systematic characterisation of night sweats

Done

True night sweats definition

Soaking through nightwear and bedding requiring a change — distinguish from normal warmth/hot bedroom. "Do you have to change your clothes?"

Duration and frequency

Acute (<2 weeks) vs chronic (>4 weeks); every night vs occasional; severity and distress to sleep

Associated fever

Subjective fever, rigors, chills? Documented temperature? Pattern (hectic, remitting, relapsing-remitting)?

Constitutional symptoms

Unintentional weight loss (how much, over what period? — objective weight where possible); fatigue; anorexia; malaise → concerning constitutional symptoms (malignancy/TB)

Other symptoms

Cough, haemoptysis, breathlessness, diarrhoea, pruritus or pain

Menopausal symptoms

Women 45–55: hot flushes, irregular periods, mood change, urogenital symptoms → menopause likely. Do not attribute automatically to menopause if there is unexplained weight loss, persistent fever, lymphadenopathy, respiratory symptoms, abnormal examination or blood results, or recent onset with no other menopausal features

Medications

SSRIs/SNRIs (a recognised cause); opioids; antipyretics (and masking fever); corticosteroids and withdrawal; thyroid replacement excess; hypoglycaemic treatment; tamoxifen and hormonal therapies (including GnRH analogues); calcium-channel blockers (e.g. nifedipine) and nitrates; alcohol and recreational drugs. Confirm the temporal association and check for other causes

Endocrine symptoms

Palpitations + sweating + weight loss → hyperthyroidism; episodic hypertension + headache + sweating → phaeochromocytoma (rare)

TB risk factors

TB contact; birth in or travel to higher-incidence countries; homelessness, prison, drug or alcohol misuse; prior TB; immunosuppression (HIV, biologics, steroids)

Sleep and breathing

Snoring, witnessed apnoeas, choking arousals, morning headache, daytime sleepiness → obstructive sleep apnoea

Alcohol and drugs

Units per week; withdrawal sweats; opioid use or withdrawal; recreational stimulants

Pattern clue

Sweats with flushes by day and night in a woman with changing periods → vasomotor; sweats with rigors and fever spikes → infection; sweats with itch after bathing → consider lymphoma or a myeloproliferative disorder

Ideas, concerns, expectations

Many patients fear cancer or HIV — ask directly, because naming the worry often shapes which tests are reassuring

The definition of "true night sweats" matters — many people who report night sweats are simply warm in bed, whereas drenching sweats that soak nightwear or bedding are more likely to have an organic cause. Antidepressants (SSRIs and SNRIs) are a recognised drug cause of sweating, so a medication review can avoid unnecessary testing. Confirm the temporal association of any new medicine with the onset of sweats, check for other causes, and avoid abrupt antidepressant withdrawal. The menopausal history is the highest-yield question in women aged 45–55.

Diagnose

Classification — Identify the aetiology category

Done

Physiological / environmental

Warm bedroom, heavy bedding, warm partner, alcohol before bed — history only; no investigation needed

Menopause / POI

Most common cause in women 45–55; declining oestrogen → altered thermoregulation. Also POI in women <40.

Drug-induced

SSRIs, SNRIs, opioids, corticosteroids (and withdrawal), excess thyroid replacement, hypoglycaemic treatment, tamoxifen, GnRH agonists, antipsychotics, nitrates, calcium channel blockers

Infection

TB (classic), HIV, infective endocarditis, osteomyelitis, abscess, brucellosis, malaria (travel)

Malignancy

Lymphoma (Hodgkin's, NHL) — most important; leukaemia; solid tumours with systemic features

Endocrine

Hyperthyroidism; hypoglycaemia (nocturnal — check HbA1c in diabetics); phaeochromocytoma (rare but treatable)

Other systemic

Obstructive sleep apnoea (night sweats may occur but are not a diagnostic feature); GORD; anxiety/panic disorder; autoimmune disease (SLE, RA)

Idiopathic

Only after a reassuring assessment, and with clear safety-netting — the absence of a diagnosis after a negative initial work-up is not by itself evidence that the sweats are idiopathic; re-examine if anything changes

Separating the common from the serious

Afebrile, weight-stable, normal nodes, clear vasomotor or drug explanation → manage in primary care. Fever, weight loss, nodes, splenomegaly, cough or abnormal FBC → investigate as in steps 4–6.

Menopause and drug side effects account for the majority of night sweats in primary care — the key task is risk-stratifying so that the less common serious causes (lymphoma, TB, HIV) are investigated when the features point to them. Obstructive sleep apnoea may be associated with night sweats, but sweats are not a diagnostic feature — assess for OSAHS when there are at least two features such as snoring, witnessed apnoeas, unrefreshing sleep, waking headache, excessive sleepiness, nocturia, choking, fragmented sleep or cognitive dysfunction (NICE NG202). Nocturnal hypoglycaemia in diabetics on sulphonylureas or insulin is a serious and completely reversible cause that requires medication review. Phaeochromocytoma is rare but is a must-not-miss cause of episodic sweating with headache, palpitations and hypertension. Carcinoid syndrome (flushing with diarrhoea) and hyperthyroidism (weight loss with good appetite, tremor, heat intolerance) are other endocrine causes worth a single screening question.

Diagnose

Examination — Systematic physical assessment

Done

Observations

Temperature, pulse, BP, oxygen saturation and weight — document accurately. Fever + night sweats → infection / haematological malignancy. Afebrile → menopause, drugs, anxiety more likely.

Lymph nodes

Full lymph node examination (cervical, supraclavicular, axillary, inguinal, epitrochlear). Hard, non-tender, rubbery nodes → lymphoma

Thyroid

Goitre, tremor, tachycardia, lid lag, exophthalmos → hyperthyroidism

Cardiovascular

New murmur (endocarditis); irregular pulse (AF associated with thyrotoxicosis); BP (phaeochromocytoma: labile hypertension)

Chest / respiratory

Dullness to percussion, bronchial breathing → TB; bilateral hilar lymphadenopathy on CXR → sarcoidosis/lymphoma

Abdomen

Spleen and liver: hepatosplenomegaly → haematological malignancy, infections (EBV, CMV, HIV); masses; liver disease stigmata

Alcohol withdrawal

Tremor, tachycardia, agitation, confusion — signs of withdrawal (see step 7)

BMI and weight trend

Document weight. Compare with the last recorded weight in the notes — an objective fall is more reliable than recall.

Breast and testes

Examine where relevant: breast lumps in women; testicular mass in young men (can present with systemic symptoms)

Mouth and teeth

Dental abscess or poor dentition (endocarditis source); oral candida or hairy leukoplakia (HIV)

Skin

Pallor (anaemia), jaundice, rashes (HIV seroconversion, SLE), Kaposi's sarcoma (HIV), night sweat soaking visible

Lymph node examination is the highest-yield component of the physical examination for night sweats — rubbery, non-tender, matted nodes in a young person with weight loss and night sweats should prompt consideration of a suspected cancer pathway referral for lymphoma. Hepatosplenomegaly is a key examination finding that markedly increases the probability of haematological malignancy or systemic infection. Documenting and comparing serial weights is more sensitive than asking patients "have you lost weight?" — patients often underestimate significant weight loss.

Diagnose

Investigations — Targeted, when unexplained or persistent

Done

Initial (persistent, unexplained or clinically significant sweats)

FBC (blood film if abnormal or haematological disease suspected); CRP / ESR; Renal and liver function where clinically indicated; TSH if symptoms/signs of thyroid disease; Glucose / HbA1c when diabetes or nocturnal hypoglycaemia is plausible. Not a routine panel for every patient — excess testing generates false positives. LDH is nonspecific and is not a screening test for lymphoma

Infection screen

HIV test if clinically indicated — by symptoms, risk, indicator condition (e.g. unexplained fever, weight loss or lymphadenopathy) or local prevalence (NICE NG60; QS157); night sweats alone are not a listed universal indication; Chest X-ray if respiratory symptoms, persistent fever, weight loss, haemoptysis, TB risk or abnormal chest examination; blood cultures if febrile with suspected bacteraemia/endocarditis, ideally before antibiotics — not for uncomplicated afebrile night sweats

TB workup

3 deep-cough sputum samples (preferably including one early-morning sample) for microscopy and culture when pulmonary TB is suspected and/or the chest X-ray suggests TB (NICE NG33); rapid molecular testing where indicated by the TB service/laboratory; no sputum induction in an ordinary GP consultation room; IGRA/Mantoux tests show TB infection but do not on their own diagnose active TB; refer suspected active TB to the TB service

Endocrine workup

Menopause is a clinical diagnosis over 45 — do not use FSH to diagnose it in women aged 45+ with typical symptoms; FSH can be considered at 40–45 with symptoms and a change in periods, and in women under 40 with suspected premature ovarian insufficiency (two FSH levels 4–6 weeks apart) (NICE NG23); plasma free or urine metanephrines only when there is a convincing paroxysmal hypertension/headache/palpitations syndrome; hyperthyroidism: TSH first, then FT4 and FT3 if TSH is low, and TRAb to help confirm Graves' disease (NICE NG145)

Haematology

Blood film (abnormal lymphocytes → lymphoma/leukaemia); serum protein electrophoresis and serum free light chains if myeloma is suspected (see step 1), according to local pathway

Imaging

Chest X-ray — reasonable in persistent unexplained night sweats with respiratory symptoms, fever, weight loss, haemoptysis, TB risk, abnormal examination or other concerning features; not automatically required for isolated occasional sweats with a clear medication or menopausal explanation. The NICE NG12 urgent chest X-ray applies to adults 40 and over with 2 or more unexplained symptoms from cough, fatigue, shortness of breath, chest pain, weight loss or appetite loss (1 or more if they have ever smoked), not night sweats alone; unexplained haemoptysis at 40 and over is a direct suspected cancer pathway referral. CT chest/abdomen/pelvis — for lymphadenopathy / lymphoma staging (hospital-led)

Do NOT routinely

PET-CT (hospital specialist); bone marrow biopsy (haematology); CT without red flags in young patients — radiation risk vs yield

Other tests by picture

Blood cultures ×3 before antibiotics if endocarditis possible; malaria testing only with an appropriate travel and fever history; EBV serology in young adults with sore throat and nodes; calcium when malignancy, myeloma or sarcoidosis is suspected; ferritin where relevant; urinalysis

Reading the results

Lymphocytosis or blasts on the film → same-day haematology advice. Raised calcium → check PTH/myeloma screen. Raised ESR with anaemia in an older adult → myeloma screen. A normal first panel does not exclude lymphoma if nodes are present — the node, not the blood test, drives the referral.

LDH is non-specific and is not a screening test for lymphoma; it may be useful in a specialist or haematological work-up but is not a routine primary-care test for night sweats. HIV testing should be offered where HIV is part of the differential diagnosis or an indicator condition is present (NICE NG60; QS157; BHIVA/BASHH/BIA testing guidance), and NICE NG60 (2016) also recommends offering an HIV test to everyone registering with a practice, and to those having blood tests, in areas of high and extremely high HIV prevalence. Where indicated, the chest X-ray is a useful test for both TB and mediastinal lymphoma, but it is not needed for every patient with isolated sweats and a clear explanation. Metanephrines have replaced catecholamines as the preferred screening test for phaeochromocytoma because they are more sensitive.

Refer

Referral Criteria — Urgent, suspected cancer, and routine pathways

Done

Same-day / 999

Sepsis, haemodynamic instability or severe systemic illness; suspected endocarditis (per local pathway); severe respiratory compromise; suspected active TB with significant illness; acute neurological symptoms; severe alcohol withdrawal; blasts or a very concerning blood film; severe immunosuppression with fever or suspected opportunistic infection

Suspected cancer: Haematology

NICE NG12 (updated April 2026): adults with unexplained lymphadenopathy (Hodgkin or non-Hodgkin lymphoma) or unexplained splenomegaly (non-Hodgkin lymphoma), weighing associated fever, night sweats, shortness of breath, pruritus or weight loss → consider a suspected cancer pathway referral (night sweats alone do not mandate referral); children and young people → consider very urgent referral per NG12 and the current local paediatric pathway; blood film or FBC suggesting acute leukaemia → immediate (same-day) specialist haematology assessment

Suspected cancer: lung

NICE NG12: chest X-ray findings suggesting lung cancer, or unexplained haemoptysis at 40 or over → suspected cancer pathway referral for lung cancer

Urgent TB Service

Suspected active TB (e.g. cough, sweats and CXR changes) — urgent referral to the local TB service (NICE NG33); advise respiratory hygiene and avoiding contact with vulnerable people until assessed; do not manage with repeated empirical antibiotics. Contact the local TB service/UKHSA health protection team promptly when active TB is suspected; formal notification follows the appropriate clinical/public-health pathway — check the local health-protection procedure

Endocrinology

Suspected phaeochromocytoma (convincing episodic hypertension + headache + palpitations/sweating); confirmed hyperthyroidism (NICE NG145) — pregnancy or conception planning needs specific specialist advice

Sleep Clinic

Suspected OSAHS — at least two features such as snoring, witnessed apnoeas, unrefreshing sleep, waking headache, excessive sleepiness, nocturia, choking, fragmented sleep or cognitive dysfunction; use the Epworth Sleepiness Scale but not as the sole basis for referral, and consider STOP-Bang → refer for diagnostic sleep testing (NICE NG202, 2021); urgently if the person drives for work or has a safety-critical job; advise on DVLA rules for excessive sleepiness

Menopause specialist

Complex risk or uncertainty, breast cancer, unexplained bleeding, premature ovarian insufficiency, or HRT contraindicated (e.g. VTE history) with severe menopausal symptoms (NICE NG23)

Primary care manage

Environmental (cooling, lighter bedding, trigger reduction); drug-induced (review medications); menopause (HRT after risk assessment, or menopause-specific CBT); no cause after a reassuring assessment, with clear safety-netting; lifestyle modification

The lymphoma suspected cancer pathway referral is designed for unexplained lymphadenopathy or splenomegaly, weighted by associated symptoms — do not delay it when those features are present. CT scanning and bone marrow biopsy for staging are time-critical. TB is a notifiable disease (Health Protection (Notification) Regulations 2010) — when active TB is suspected, contact the local TB service/UKHSA health protection team promptly, following the local health-protection procedure for formal notification; contact tracing follows, and there is no need to wait for culture. Identifying OSAHS is worthwhile because CPAP improves sleepiness and quality of life, and treated OSA is compatible with driving — but night sweats are not themselves a diagnostic feature of OSA.

Treat

Treatment — Cause-directed management ladder

Done

Menopausal night sweats

HRT 1st line

HRT is the most effective treatment for vasomotor symptoms (NICE NG23). Offer combined HRT (oestrogen + progestogen) if the uterus is present, and oestrogen-only HRT after total hysterectomy. Discuss breast, VTE, cardiovascular and bleeding risks. NICE states that VTE risk is not increased with standard-dose transdermal HRT, whereas oral HRT increases VTE risk — consider transdermal where VTE risk is increased, including BMI over 30; individual baseline risk still requires assessment. Review at 3 months, then annually. Seek specialist advice for complex risk, breast cancer, unexplained bleeding, POI or uncertainty.

SSRI-induced

Medication review

Confirm the timing fits. Check for other causes. Options, only where clinically safe: reduce the dose, or switch agent if the mood disorder allows — note venlafaxine commonly causes sweating, so it is not a switch for antidepressant-induced sweats. Discuss the balance with the patient rather than stopping abruptly.

HRT contraindicated (menopause)

Non-hormonal options

Menopause-specific CBT is an evidence-based option. Fezolinetant is a NICE option when HRT is unsuitable, subject to its prescribing and monitoring requirements. NICE advises against routinely offering SSRIs, SNRIs or clonidine as first-line treatment for vasomotor symptoms alone; off-label options such as venlafaxine, some SSRIs or gabapentin are less effective than HRT — use the local formulary for doses; avoid paroxetine and fluoxetine in women taking tamoxifen (they reduce its activation — see BNF interactions). For women after breast cancer, agree the plan with the oncology team.

Nocturnal hypoglycaemia

Medication review

Reduce sulphonylurea dose; review insulin regimen; bedtime snack; CGM to confirm pattern; endocrinology if complex.

HyperthyroidismTSH first, then FT4 and FT3 if TSH is low; TRAb to help confirm Graves' disease. Refer to endocrinology; a beta-blocker/supportive treatment where appropriate (dose per local formulary), and consider an antithyroid drug (usually carbimazole) while awaiting specialist assessment, with baseline FBC and LFTs first (NICE NG145, 2019). Carbimazole safety: advise the patient to stop the drug and seek urgent assessment for fever, sore throat, mouth ulcers, bruising or infection symptoms, because of agranulocytosis; stop and do not restart if agranulocytosis develops. Carbimazole carries MHRA pregnancy/contraception warnings — pregnancy and conception planning need specialist advice.

OSAAfter diagnostic sleep testing, offer fixed-level CPAP to adults with moderate or severe OSAHS, alongside lifestyle advice; mild OSAHS may not require treatment unless symptoms affect quality of life or there are priority factors (NICE NG202, 2021). Weight loss if overweight. Reduce evening alcohol and sedatives. Consider occupational driving risk and the DVLA position where excessive sleepiness may impair driving.

TB / HIVSpecialist-led treatment. The GP role: prompt referral and liaison with the TB service/health protection team, supporting adherence, checking for drug interactions and safeguarding contacts.

AlcoholBrief intervention. Do not advise a person with alcohol dependence to stop abruptly without a withdrawal plan (withdrawal itself causes sweating and can cause seizures). Assess withdrawal risk and arrange medically assisted withdrawal where indicated. Same-day hospital assessment if there is a history of severe withdrawal, seizures, delirium tremens, significant comorbidity or current severe withdrawal symptoms.

Next steps: see Menopause and HRT · Haematological cancers · Hyperthyroidism · Snoring and sleep apnoea · HIV

HRT is the most effective treatment for menopausal vasomotor symptoms. NICE NG23 (updated November 2024) presents the risks of HRT in absolute terms so that women can weigh them for themselves; for most women under 60 the benefits for symptom control outweigh the risks. NICE states that VTE risk is not increased with standard-dose transdermal HRT, whereas oral HRT increases VTE risk, which is why transdermal is preferred for women with VTE risk factors; individual baseline risk still requires assessment. Non-hormonal drugs are less effective, SSRIs/SNRIs/clonidine are not routinely offered first-line for vasomotor symptoms alone, and fezolinetant is an option when HRT is unsuitable; menopause-specific CBT was added to NG23 in 2024 as an option alongside or instead of HRT. SSRIs and SNRIs are paradoxically both a cause of sweating and a treatment for menopausal flushes — a useful point to explain to patients.

Lifestyle

Non-Pharmacological — Environmental and behavioural modifications

Done

Cool sleeping environment Keep the bedroom cool. Fan, cooling mattress pad. Light, breathable cotton bedding. Moisture-wicking nightwear. Simple but highly effective.

Alcohol avoidance Alcohol is a potent vasodilator — reduces threshold for sweating. Avoid in the hours before bed; keep within 14 units a week (UK Chief Medical Officers' guidance, 2016).

Caffeine and triggers Some women find caffeine, alcohol and spicy food trigger flushes — a symptom diary helps identify personal triggers.

Weight management Obesity is the main risk factor for OSA and is associated with more troublesome vasomotor symptoms; modest weight loss can help both.

CBT for hot flushes CBT specifically designed for menopausal vasomotor symptoms — recommended as an option in NICE NG23 (November 2024), in addition to or instead of HRT. Available via some NHS Talking Therapies services or as guided self-help.

Layering bedclothes Use layers rather than single thick duvet — allows thermal self-regulation during sleep cycles without full arousal.

Smoking cessation Smoking is associated with more frequent and severe hot flushes and with earlier menopause. Refer to the stop-smoking service.

Sleep hygiene Regular sleep times, a spare set of nightwear by the bed, and a towel on the pillow reduce disruption while the cause is treated.

CBT for menopausal hot flushes (the MENOS trials) has demonstrated significant reduction in hot flush frequency and bother scores — comparable to pharmacological alternatives for women who cannot or choose not to use HRT. It should be offered alongside, not instead of, HRT discussion. Alcohol is a vasodilator and also causes sweating in withdrawal — an underemphasised, modifiable factor. Environmental cooling is inexpensive, safe, and immediately effective for any cause of night sweats while investigations are awaited.

Safety

Follow-Up & Safety-Netting

Done

1–2 weeks

Review clinically important results and ensure abnormal results have an action plan; confirm HIV/TB results reviewed; check drug-related cause identified and addressed

4–6 weeks

Reassess persistent symptoms or treatment response

3 months

Review any menopause treatment for effect and tolerability (NICE NG23); symptom reassessment (e.g. Greene Climacteric Scale); dose adjustment if needed

Ongoing

Individualised follow-up: arrange review to confirm that results have been checked and symptoms are improving. Further investigation is guided by persistence, progression, new symptoms, examination findings or abnormal results. Do not repeat imaging routinely when symptoms have resolved and the initial assessment was reassuring

Annual

HRT review at least annually: symptoms, bleeding pattern, BP, VTE and breast cancer risk, ongoing need; breast screening attendance; menopause specialist review if complex

Bleeding

Unscheduled bleeding on HRT that persists beyond the settling-in months needs assessment under the local bleeding-on-HRT pathway. Post-menopausal bleeding at 55 or over that is not attributable to HRT → suspected cancer pathway referral for endometrial cancer (NICE NG12, updated April 2026)

999 now

Any one of: signs of sepsis or shock (fever or rigors with collapse, confusion, fast breathing, or cold, mottled or blue skin); new neurological deficit; severe chest pain

Same day

Contact the practice (NHS 111 out of hours) the same day for fever with feeling very unwell, coughing blood, new breathlessness, or unexplained bruising, bleeding or a rash of tiny spots

Within a few days

Book a review within a few days for unexplained weight loss; persistent or documented fever; a new or enlarging lump; persistent cough; drenching sweats becoming more frequent or severe; recurrent infection; worsening general health

Remote or OOH

Convert to a same-day face-to-face assessment if fever with feeling unwell, breathlessness, coughing blood, bruising or bleeding, or a new lump is reported, or observations cannot be obtained

SCA safety-net wording

"Your blood tests and chest X-ray haven't shown anything worrying, which is reassuring. If you notice a lump in your neck, armpit or groin, lose weight without trying, get a temperature or a cough that won't go away, please book to see me within a few days rather than waiting — and I'll see you in four weeks either way."

Re-investigate if

Guided by persistence, progression, new symptoms (fever, weight loss, lymphadenopathy), new examination findings or abnormal results — not on a fixed timetable

Night sweats with a negative initial workup require a structured safety-net — lymphoma can present insidiously with a normal initial blood panel. There is no general NICE recommendation for routine repeat FBC, CRP and chest X-ray at a fixed interval; follow-up should be individualised, with re-examination and discussion with a specialist (haematology, infectious diseases or a rapid diagnostic service) when symptoms persist or progress, new features appear or results are abnormal. The absence of a diagnosis after a negative initial work-up is not evidence of an "idiopathic" cause without clear safety-netting. HIV test results require active follow-up — some patients do not return for results. NICE NG23 recommends reviewing each menopause treatment at 3 months and then at least annually — reassessing benefit, risks and ongoing need.